Capricor Therapeutics Executive Compensation (FY25)
CAPR · Executive and director compensation, fiscal 2025 only
The Capricor Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 20, 2026Latest filing (8-K): June 8, 2026
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
105 figures on this page: 97 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Capricor Therapeutics' chief executive and what were they paid?
Total compensation for Linda Marbán, Chief Executive Officer, came to $3,521,565 in fiscal 2025.
What was Capricor Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 79.6% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in Capricor Therapeutics' peer group?
The disclosed peer group includes Option and Stock.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Linda Marbán Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Anthony Bergmann Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Karen Krasney Executive Vice President & General Counsel | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Anthony Bergmann | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Karen Krasney | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Linda Marbán | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Frank Litvack, M.D Board chair | — | — | ◇ | — | — | ◇ | ◇ |
David B. Musket | ◇ | — | ◇ | — | — | — | ◇ |
George W. Dunbar Jr., M.B.A | ◇ | — | ◇ | — | — | — | ◇ |
Philip Gotwals, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Philip Gotwals | ◇ | — | — | — | — | ◇ | ◇ |
Karimah Es Sabar | ◇ | — | ◇ | — | — | — | ◇ |
Michael Kelliher | ◇ | — | ◇ | — | — | — | ◇ |
Paul Auwaerter, M.D., M.B.A | ◇ | — | ◇ | — | — | — | ◇ |
Linda Marbán, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Stock Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Option OPCH
- Stock SYBT
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 4, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 22, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 14, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 12, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 3, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 11, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 5, 2020 | = | ◇ | ◇ | ◇ |
| 2016 | June 14, 2017 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Capricor Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Capricor Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
105 figures on this page: 97 cited to the filing that reported them, 8 calculated from figures it prints.
97 cited to the filing
8 calculated from the filing
Documents cited
- 0001104659-26-071364Item 5.07 Submission of Matters of a Vote of Security Holders
- 0001104659-26-042070NON-EMPLOYEE DIRECTOR COMPENSATION
- 0001558370-25-008145Item 5.07 Submission of Matters of a Vote of Security Holders
- 0001558370-24-008310Item 5.07 Submission of Matters of a Vote of Security Holders
- 0001558370-23-011046Item 5.07 Submission of Matters of a Vote of Security Holders
- 0001558370-22-009778Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-21-082129Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001104659-20-071410Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001144204-17-033136Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Capricor Therapeutics executive compensation, FY2025.” https://intel.velarion.ai/comp/CAPR (accessed 2026).
Short form: data: Velarion
The Capricor Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Capricor Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Capricor Therapeutics discloses
The companies named in CAPR's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}